A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

This study has been completed.

Sponsored by:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00168441

Purpose

4-month study including a 30-day baseline phase

Condition	Intervention	Phase
Postherpetic Neuralgia	Drug: Botulinum Toxin Type A	Phase II

MedlinePlus related topics: Botox Shingles

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Allergan:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:

130

Eligibility

Criteria

Inclusion Criteria:

Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion Criteria:

Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	191622-066
Study First Received:	September 12, 2005
Last Updated:	September 12, 2005
ClinicalTrials.gov Identifier:	NCT00168441
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neuralgia, Postherpetic
Signs and Symptoms
Botulinum Toxins
Neuromuscular Diseases
Neuralgia

Peripheral Nervous System Diseases
Neurologic Manifestations
Pain
Botulinum Toxin Type A

Additional relevant MeSH terms:

Anti-Dyskinesia Agents
Therapeutic Uses
Physiological Effects of Drugs
Nervous System Diseases

Neuromuscular Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009